Posts Tagged ‘RED-HF’

RSS

January 16th, 2013

No Benefit of Darbepoetin Alfa in Heart Failure Patients with Anemia

The bad news continues for Aranesp (darbepoetin alfa), Amgen’s long-acting erythropoietin-stimulating agent. The company today announced the top-line results of a large phase 3 heart-failure trial of the drug and said that the trial had failed to meet its primary endpoint. The RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which started in 2006, had randomized 2278 […]